ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Position Boosted by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC grew its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMAFree Report) by 133.9% during the fourth quarter, Holdings Channel reports. The institutional investor owned 7,378 shares of the biotechnology company’s stock after acquiring an additional 4,224 shares during the period. Nisa Investment Advisors LLC’s holdings in ADMA Biologics were worth $127,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. State Street Corp increased its stake in shares of ADMA Biologics by 61.4% during the third quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock valued at $259,970,000 after acquiring an additional 4,945,063 shares during the period. Geode Capital Management LLC boosted its stake in ADMA Biologics by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 5,381,985 shares of the biotechnology company’s stock valued at $107,606,000 after purchasing an additional 137,989 shares in the last quarter. Perpetual Ltd acquired a new position in shares of ADMA Biologics during the 4th quarter valued at $62,300,000. Assenagon Asset Management S.A. raised its stake in shares of ADMA Biologics by 2.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock worth $69,454,000 after buying an additional 92,281 shares in the last quarter. Finally, Lord Abbett & CO. LLC acquired a new stake in shares of ADMA Biologics in the third quarter valued at $61,858,000. 75.68% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on ADMA shares. Raymond James lifted their target price on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a report on Friday, November 8th. HC Wainwright lifted their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, November 8th.

Check Out Our Latest Research Report on ADMA

Insider Transactions at ADMA Biologics

In related news, CFO Brad L. Tade sold 15,000 shares of the stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $21.15, for a total value of $317,250.00. Following the completion of the sale, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at approximately $4,218,007.95. This represents a 7.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.70% of the stock is currently owned by insiders.

ADMA Biologics Trading Down 1.7 %

NASDAQ:ADMA opened at $16.10 on Friday. The stock has a fifty day simple moving average of $18.31 and a 200 day simple moving average of $17.54. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $3.81 billion, a price-to-earnings ratio of 57.50 and a beta of 0.76. ADMA Biologics, Inc. has a 1-year low of $5.02 and a 1-year high of $23.64.

ADMA Biologics (NASDAQ:ADMAGet Free Report) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The business had revenue of $119.84 million for the quarter, compared to analyst estimates of $107.25 million. During the same quarter in the previous year, the business earned $0.01 earnings per share. Sell-side analysts forecast that ADMA Biologics, Inc. will post 0.51 earnings per share for the current year.

ADMA Biologics Profile

(Free Report)

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Featured Articles

Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics, Inc. (NASDAQ:ADMAFree Report).

Institutional Ownership by Quarter for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.